Skip to main content
CAH
NYSE Life Sciences

Cardinal Health's Q1 Revenue Misses Expectations; Analyst Boosts Price Target

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$195.24
Mkt Cap
$45.943B
52W Low
$136.71
52W High
$233.6
Market data snapshot near publication time

summarizeSummary

Cardinal Health reported Q1 revenue of $60.94 billion, falling short of analyst estimates of $62.28 billion. The company also reported adjusted EPS of $3.17 and reiterated its full-year adjusted EPS guidance at approximately $10.75. While TD Cowen maintained a Buy rating and raised its price target to $255 from $251, the revenue miss is a significant update. This news follows yesterday's SEC filings (8-K and 10-Q) which reported Q3 results and guidance. The 'Q1' designation in this report is likely a typo for 'Q3', providing more specific details on the recently announced earnings. The reported revenue miss contradicts the 'strong Q3 non-GAAP results' previously highlighted in the 8-K, making this a material clarification for traders.

At the time of this announcement, CAH was trading at $195.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $45.9B. The 52-week trading range was $136.71 to $233.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


show_chartPrice Chart

Share this article

Copied!

feed CAH - Latest Insights

CAH
May 01, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
8
CAH
Apr 30, 2026, 8:51 AM EDT
Filing Type: 10-Q
Importance Score:
7
CAH
Apr 30, 2026, 6:47 AM EDT
Filing Type: 8-K
Importance Score:
8
CAH
Apr 30, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
CAH
Feb 05, 2026, 8:47 AM EST
Filing Type: 10-Q
Importance Score:
8
CAH
Feb 05, 2026, 6:47 AM EST
Filing Type: 8-K
Importance Score:
8
CAH
Jan 13, 2026, 6:53 AM EST
Filing Type: 8-K
Importance Score:
7